 | 
|
| |
|
Titel: Handläggning av svårt skov av ulcerös kolit [summary] (serie: Tema kronisk tarminflammation) 2009 nr 45 sid 2994-8
|
Summary:
A severe attack is seen in approximately 15 % of patients with ulcerative colitis. Early recognition of the disease, prompt initiation of medical treatment and objective evaluation of response to therapy are crucial in the management of the patient. The present mortality rate is below 1%, but colectomy rates have remained unchanged at about 30%. Close collaboration between the gastroenterologist and the surgeon is therefore essential. Corticosteroids remain a mainstay in the treatment. Early recognition of steroid-resistant disease is important in order to offer these patients rescue medical therapy or colectomy. Ciclosporin use has been limited in Sweden because of concerns about toxicity. Rescue therapy with a single infusion of infliximab has reduced colectomy rates at 3 months and at follow-up 3 years later. The optimal rescue therapy and the most effective maintenance treatment need to be defined by future trials.
Tysk C, Almer S, Andersson M, Befrits R, Hertervig E, Kilander A, Lindgren S, Suhr O.
Correspondence: Curt Tysk, Sektionen för gastroenterologi, Medicinska kliniken, Universitetssjukhuset, SE-701 85 Örebro, Sweden curt.tysk@orebroll.se
Referenser:
1.Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005;19 Suppl A:5-36.
2.Stange EF, Travis SP, Vermeire S, Reinisch W, Geboes K, Barakauskiene A, et al. European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. Journal of Crohn's and Colitis 2008;2:1-23.
3.Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol 2007;5(1):103-10.
4.Travis SPL, Stange EF, Lémann M, Öresland T, Bemelman WA, Chowers Y, et al. European evidence-based consensus on the management of ulcerative colitis: current management. Journal of Crohn's and Colitis 2008;2:24-62.
5.Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955;2(4947):1041-8.
6.D'Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007;132(2):763-86.
7.Seo M, Okada M, Yao T, Ueki M, Arima S, Okumura M. An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol 1992;87(8):971-6.
8.Lindgren SC, Flood LM, Kilander AF, Löfberg R, Persson TB, Sjödahl RI. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol 1998;10(10):831-5.
9.Travis SP, Farrant JM, Ricketts C, Nolan DJ, Mortensen NM, Kettlewell MG, et al. Predicting outcome in severe ulcerative colitis. Gut 1996;38(6):905-10.
10.Almer S, Bodemar G, Franzen L, Lindstrom E, Nystrom P, Strom M. Use of air enema radiography to assess depth of ulceration during acute attacks of ulcerative colitis. Lancet 1996;347(9017):1731-5.
11.Almer S, Bodemar G, Franzen L, Lindström E, Noren B, Ström M. Plain X-ray films and air enema films reflect severe mucosal inflammation in acute ulcerative colitis. Digestion 1995;56(6):528-33.
12.Almer S, Bodemar G, Lindström E, Peters AM, Ström M. Air enema radiology compared with leukocyte scintigraphy for imaging inflammation in active ulcerative colitis. Eur J Gastroenterol Hepatol 1995;7(1):59-64.
13.Almer S, Franzen L, Peters AM, Tjadermo M, Ekberg S, Granerus G, et al. Do technetium-99m hexamethylpropylene amine oxime-labeled leukocytes truly reflect the mucosal inflammation in patients with ulcerative colitis? Scand J Gastroenterol 1992;27(12):1031-8.
14.Alemayehu G, Järnerot G. Colonoscopy during an attack of severe ulcerative colitis is a safe procedure and of great value in clinical decision making. Am J Gastroenterol 1991;86(2):187-90.
15.Carbonnel F, Lavergne A, Lemann M, Bitoun A, Valleur P, Hautefeuille P, et al. Colonoscopy of acute colitis. A safe and reliable tool for assessment of severity. Dig Dis Sci 1994;39(7):1550-7.
16.Schumacher G, Ljungh A, Sandstedt B. Inflammatorisk tarmsjukdom eller infektiös kolit? Klinisk bild, mikrobiologi och histologi ger vägledning Läkartidningen 1995;92(42):3885-9.
17.Jakobovits SL, Travis SP. Management of acute severe colitis. Br Med Bull 2006;75-76:131-44.
18.Järnerot G, Rolny P, Sandberg-Gertzen H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology 1985;89(5):1005-13.
19.Arts J, D'Haens G, Zeegers M, Van Assche G, Hiele M, D'Hoore A, et al. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis 2004;10(2):73-8.
20.Campbell S, Travis S, Jewell D. Ciclosporin use in acute ulcerative colitis: a long-term experience. Eur J Gastroenterol Hepatol 2005;17(1):79-84.
21.Shibolet O, Regushevskaya E, Brezis M, Soares-Weiser K. Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev 2005(1):CD004277.
22.Ogata H, Matsui T, Nakamura M, Iida M, Takazoe M, Suzuki Y, et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 2006;55(9):1255-62.
23.Armuzzi A, De Pascalis B, Lupascu A, Fedeli P, Leo D, Mentella MC, et al. Infliximab in the treatment of steroid-dependent ulcerative colitis. Eur Rev Med Pharmacol Sci 2004;8(5):231-3.
24.Järnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlen P, Grännö C, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005;128(7):1805-11.
25.Ochsenkuhn T, Sackmann M, Goke B. Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study. Eur J Gastroenterol Hepatol 2004;16(11):1167-71.
26.Probert CS, Hearing SD, Schreiber S, Kuhbacher T, Ghosh S, Arnott ID, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 2003;52(7):998-1002.
27.Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353(23):2462-76.
28.Sands BE, Tremaine WJ, Sandborn WJ, Rutgeerts PJ, Hanauer SB, Mayer L, et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 2001;7(2):83-8.
29.Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006;3:CD005112.
30.Gustavsson A, Järnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlen P, et al. Colectomy after rescue therapy in intravenous-steroid resistant acute ulcerative colitis: A 3-year follow-up study of the Swedish-Danish infliximab/placebo trial. Gut 2008;57(Suppl II):A79.
31.Dickinson RJ, Ashton MG, Axon AT, Smith RC, Yeung CK, Hill GL. Controlled trial of intravenous hyperalimentation and total bowel rest as an adjunct to the routine therapy of acute colitis. Gastroenterology 1980;79(6):1199-204.
32.McIntyre PB, Powell-Tuck J, Wood SR, Lennard-Jones JE, Lerebours E, Hecketsweiler P, et al. Controlled trial of bowel rest in the treatment of severe acute colitis. Gut 1986;27(5):481-5.
33.Gonzalez-Huix F, Fernandez-Banares F, Esteve-Comas M, Abad-Lacruz A, Cabre E, Acero D, et al. Enteral versus parenteral nutrition as adjunct therapy in acute ulcerative colitis. Am J Gastroenterol 1993;88(2):227-32.
34.Bernstein CN, Blanchard JF, Houston DS, Wajda A. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost 2001;85(3):430-4.
35.Irving PM, Pasi KJ, Rampton DS. Thrombosis and inflammatory bowel disease. Clin Gastroenterol Hepatol 2005;3(7):617-28.
36.Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004;53 Suppl 5:V1-16.
37.Shen J, Ran ZH, Tong JL, Xiao SD. Meta-analysis: The utility and safety of heparin in the treatment of active ulcerative colitis. Aliment Pharmacol Ther 2007;26(5):653-63.
38.Perencevich M, Burakoff R. Use of antibiotics in the treatment of inflammatory bowel disease. Inflamm Bowel Dis 2006;12(7):651-64.
39.Criscuoli V, Casa A, Orlando A, Pecoraro G, Oliva L, Traina M, et al. Severe acute colitis associated with CMV: a prevalence study. Dig Liver Dis 2004;36(12):818-20.
40.Dzabic M, Rahbar A. Aktiv HCMV-infektion bakom akut inflammatorisk tarmsjukdom. Kausal roll eller epifenomen återstår att bevisa. Läkartidningen 2008;105:1378-81.
41.Domenech E, Vega R, Ojanguren I, Hernandez A, Garcia-Planella E, Bernal I, et al. Cytomegalovirus infection in ulcerative colitis: a prospective, comparative study on prevalence and diagnostic strategy. Inflamm Bowel Dis 2008;14(10):1373-9.
42.Sands BE, Sandborn WJ, Feagan B, Lofberg R, Hibi T, Wang T, et al. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology 2008;135(2):400-9.
43.Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2006(2):CD000544.
44.Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi Porro G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006;55(1):47-53.
45.Timmer A, McDonald JW, Macdonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2007(1):CD000478.
46.Gustavsson A, Halfvarson J, Magnuson A, Sandberg-Gertzen H, Tysk C, Järnerot G. Long-term colectomy rate after intensive intravenous corticosteroid therapy for ulcerative colitis prior to the immunosuppressive treatment era. Am J Gastroenterol 2007;102(11):2513-9.
 2994 |
 2995 |
 2996 |
 2997 |
 2998 |